ArticleCells2022
Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Efficacy and safety of PI3K inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Article
- Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.Breast (Edinburgh, Scotland) · 2026Article
- Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2- metastatic breast cancer.Pathologica · 2025Review
- PTEN hamartoma of soft tissue (PHOST) and fibroadipose vascular anomaly (FAVA): a comparative clinicopathologic and molecular analysis.Virchows Archiv : an international journal of pathology · 2025Article
- Harmonization trial onThe journal of liquid biopsy · 2025Article
- International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors.The journal of liquid biopsy · 2025Review
- ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.Breast cancer research : BCR · 2025Article
- Deep learning algorithm on H&E whole slide images to characterizeComputational and structural biotechnology journal · 2024Article
- LATS2 and FAT4 as key candidate genes of hippo pathway associated with the risk and progression of breast cancer: an in-silico approach.Scientific reports · 2024Article
- Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients.Scientific reports · 2024Article
- Highly consistency ofHeliyon · 2024Article
- Review
- The molecular landscape of breast mucoepidermoid carcinoma.Cancer medicine · 2023Article
- Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution.Cancers · 2023Review
- Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers.Frontiers in molecular biosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Somatic mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.